Max Healthcare shares are in focus following a solid Q3FY25 performance, though HSBC has maintained a Hold rating, signaling cautious optimism despite operational improvements. The stock is currently trading at ₹1,067, slightly above HSBC’s target price of ₹1,015, implying a modest 5% downside from current levels.
HSBC noted that Max Healthcare delivered an operational beat in Q3FY25, driven by a better-than-expected pick-up in new hospitals. This performance highlights the company’s strong growth trajectory in expanding its healthcare network. However, the profit after tax (PAT) was impacted by one-off items, which weighed on the bottom line.
While the Q3 results indicate robust operational execution, HSBC remains cautious given Max Healthcare’s ongoing expansion spree. The brokerage emphasized that there is no room for slippage in the execution of new hospitals, as any delays or inefficiencies could affect future profitability and growth prospects.
With the stock currently trading above HSBC’s target price, the near-term upside appears limited, and the market will closely watch how effectively Max Healthcare manages its expansion while maintaining operational efficiency.
(Disclaimer: This article is for informational purposes only and does not constitute financial advice. Investors should consult their financial advisors before making any investment decisions.)